Keywords
Hematological diseases
Hematological tests
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To describe the hematological manifestations in patients with Systemic Lupus Erythematosus (SLE) hospitalized at a referral center, analyzing their clinical-epidemiological profile, laboratory findings, and outcomes. Methods: Observational, descriptive, cross-sectional, and retrospective study based on the analysis of medical records from January 2022 to August 2023. Results: Among 70 patients, 88.6% were women, with a predominant age range of 25 to 34 years (44.3%). The most commonly used medications were prednisone (98.6%) and hydroxychloroquine (97.1%). Anemia was the most prevalent hematological abnormality (91.4%), followed by lymphopenia (57.1%), thrombocytopenia (21.4%), and neutropenia (7.1%). Antinuclear antibodies were present in 94.3% of patients, followed by anti-Ro/SS-A (40%) and anti-Sm (34.3%). Antiphospholipid autoantibodies were absent in 72.9% of cases. Autoimmune hemolytic anemia was not identified. Prolonged hospitalization (>15 days) occurred in 71.4% of patients. Conclusion: The study reinforces the need for close and individualized monitoring of these patients, highlighting the importance of early identification and proper management of hematological manifestations throughout the disease course.
References
ABU-SHAKRA M, et al. Anticardiolipin antibodies in systemic lupus erythematosus: Clinical and laboratory correlations. The American Journal of Medicine, 1995; 99(6): 624–8.
ALENCAR PES, et al. Lúpus eritemato sosistêmico (LES) em atividade desencadeada por sepse secundária a infecção de trato urinário, associado a manifestação inicial de herpes genital. Brazilian Journal of Implantology and Health Sciences, 2024; 6(3): 2884–95.
AL-HOMOOD IA. Thrombosis in Systemic Lupus Erythematosus: A Review Article. ISRN Rheumatol, 2012; 2012: 428269.
BENEDEK TG. William Osler and development of the concept of systemic lupus erythematosus. Seminars in Arthritis and Rheumatism, 1997; 27(1): 48–56.
COZIER YC, et al. A prospective study of reproductive factors in relation to risk of systemic lupus erythematosus among black women. Lupus, 2021; 30(2): 204-210.
CUCHACOVICH R e GEDALIA A. Pathophysiology and clinical spectrum of infections in systemic lupus erythematosus. Rheumatic Diseases Clinics of North America, 2009; 35(1): 75–93.
DIAS AMB, et al. White blood cell count abnormalities and infections in one-year follow-up of 124 patients with SLE. Annals of the New York Academy of Sciences, 2009; 1173: 103–7.
FARIAS VFR, et al. Análise do perfil de transfusões de hemocomponentes em um hospital de Belém do Pará no ano de 2022. Revista Eletrônica Acervo Saúde, 2025; 25(10): 19685.
FAYYAZ A, et al. Haematologicalmanifestationsoflupus. Lupus Science & Medicine, 2015; 2(1): 78–8.
GALIL SMA, et al. Prognostic significance of platelet count in SLE patients. Platelets, 2016; 28(2): 203–7.
GOLDMAN L e SCHAFER AI. Goldman-Cecil Medicina Interna. Rio de Janeiro: Elsevier, 2011; 23: 3590.
IABONI A, et al. Fatigue in systemic lupus erythematosus: contributions of disordered sleep, sleepiness, and depression. The Journal of Rheumatology, 2006; 33(12): 2453–7.
KLEIN A e MOLAD Y. Hematological Manifestations among Patients with Rheumatic Diseases. Acta Haematologica, 2020; 144(4): 403–12.
LERTCHAISATAPORN K, et al. An evaluation of the association of leukopenia and severe infection in patients with systemic lupus erythematosus. Journal of Clinical Rheumatology, 2013; 19(3): 115–20.
LINDELÖF L, et al. A survey of ficolin-3 activity in Systemic Lupus Erythematosus reveals a link to hematological disease manifestations and autoantibody profile. Journal of Autoimmunity, 2024; 143: 103166–6.
MAGALHÃES MB, et al. Manifestaçõesclínicas do lúpuseritematososistêmico: abordagemdiagnóstica e terapêuticana sala de urgência. Medicina (Ribeirao Preto Online), 2003; 36(2/4): 409.
MARTÍNEZ-BAÑOS D, et al. Moderate and severe neutropenia in patients with systemic lupus erythematosus. Rheumatology, 2006; 45(8): 994–8.
MEYER A, et al. Systemic lupus erythematosus and neutropaenia: a hallmark of haematological manifestations. Lupus Science & Medicine, 2020; 7(1): 399.
MIRANDA-HERNÁNDEZ D, et al. Active haematological manifestations of systemic lupus erythematosus lupus are associated with a high rate of in-hospital mortality. Lupus, 2016; 26(6): 640–5.
MIRZAYAN MJ, et al. Prognostic parameters for flare in systemic lupus erythematosus. Rheumatology, 2000; 39(12): 1316–9.
MUSTONEN P, et al. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study. Lupus, 2014; 23(14): 1468-76.
NURI E, et al. Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. Immunologic Research, 2017; 65(1): 17–24.
RIBEIRO PDC, et al. Manual de reumatologia. Rio de Janeiro: Guanabara Koogan, 2020; 2: 468.
SANTACRUZ JC, et al. A Practical Perspective of the Hematologic Manifestations of Systemic Lupus Erythematosus. Cureus, 2022; 14(3): 22938.
SCOFIELD RH, et al. Thrombocytopenia identifies a severe familial phenotype of systemic lupus erythematosus and reveals genetic linkages at 1q22 and 11p13. Blood, 2003; 101(3): 992-7.
SHINJO SK, et al. Livro da Sociedade Brasileira de Reumatologia. Barueri: Manole; 2021; 2: 920.
UNLU O, et al. The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. European Journal of Rheumatology, 2016; 3(2): 75-84.
VELO-GARCÍA A, et al. The diagnosis and management of the haematologic manifestations of lupus. Journal of autoimmunity, 2016; 74: 139-160.
VILÁ LM, et al. Systemic lupus erythematosus in a multiethnic US cohort, XXXVII: Association of lymphopenia with clinical manifestations, serologic abnormalities, disease activity, and damage accrual. Arthritis & Rheumatism, 2006; 55(5): 799-806.
ZIAKAS PD, et al. Lupus thrombocytopenia: clinical implications and prognostic significance. Annals of the Rheumatic Diseases, 2005; 64(9): 1366-9.